Skip to main content Skip to section navigation Skip to footer
SCYNEXIS, Inc. SCYNEXIS, Inc.
  • About Us
    • Our Mission
    • Leadership
    • Partnerships
    • Careers
    • Contact Us
  • Our Science
    • Ibrexafungerp
    • Life-threatening Infections
    • Community Infections
    • Pipeline
    • Publications and Presentations
  • Our Product
  • News
    • News
    • Events
  • Careers
  • Investors
    • News & Events
    • Company Info
    • Financial Info
    • Stock Info
    • SEC Filings
    • Governance

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Leadership
    • Contacts
    • FAQ
    • Tear Sheet
  • Financial Info
    • Overview
    • Financial Results
    • Key Ratios
    • Investor Calculator
  • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • Investor Calculator
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Filings
    • Quarterly Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
Mar 26, 2020 8:00am EDT

SCYNEXIS to Virtually Present on the Candida Auris Treatment Landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020

Mar 11, 2020 8:18am EDT

SCYNEXIS Reports Full Year 2019 Financial Results and Provides Company Update

Mar 05, 2020 8:00am EST

SCYNEXIS Announces Preclinical Data on Ibrexafungerp and Azoles against Aspergillus Presented at the 9th Advances Against Aspergillosis and Mucormycosis Conference

Feb 13, 2020 8:08am EST

SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)

Jan 08, 2020 7:30am EST

SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting

Dec 16, 2019 8:30am EST

SCYNEXIS Appoints Business Development Veteran Philippe Tinmouth to its Board of Directors

Dec 12, 2019 12:46pm EST

SCYNEXIS Announces Closing of $35 Million Public Offering of Common Stock and Warrants

Dec 10, 2019 6:22am EST

SCYNEXIS Announces Pricing of $35 Million Public Offering of Common Stock and Warrants

Dec 09, 2019 4:01pm EST

SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants

Nov 14, 2019 8:30am EST

SCYNEXIS Commends the CDC for the Recognition of Candida auris as a New "Urgent Threat" in its Updated Report on Antibiotic Resistance Threats in the United States

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • …
  • Page 31
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
Scynexis
1 Evertrust Plaza, Jersey City, NJ 07302
(201) 884-5485
Facebook Twitter Linkedin
  • Patents
  • Expanded Access
  • Privacy Policy
  • Disclaimer
  • Sitemap
© 2023 SCYNEXIS, Inc. All Rights Reserved.